Please assess the completion status of the following clinical trial:

Trial Title: Subconjunctival Bevacizumab and Recurrent Pterygium

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recurrent pterygium~Exclusion Criteria:~* Pregnant or lactating women~* History of myocardial infarction~* History of stroke

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Subconjunctival Bevacizumab (Type: EXPERIMENTAL): One aplication of subconjunctival Bevacizumab 0,5 ml

Based on this trial design, predict the completion outcome and termination type (if applicable).